INTRODUCTION
Immunologic adjuvants are agents that nonspecifically increase immune responses to specific antigens that are weakly immunogenic. The purpose of this article is to inform investigators and research staff about three commonly used and commercially available adjuvants for antibody production in laboratory animals and to briefly cover other adjuvants that may be used for this purpose. The three adjuvants that will be emphasized in this article are Freund's-type mineral oil adjuvant emulsions, Ribi Adjuvant System®, and TiterMax®. Other reports have studied these adjuvants, or combinations thereof, when administered with specific antigens (Lipman et al., 1992; Smith et al., 1992; Johnston et al., 1991) .
The objective of using adjuvants differs greatly, whether in research, antisera production, or vaccine development. Adjuvants intended for production of antisera need to induce high titers of high avidity antibody within a short time. Adjuvants intended for vaccine use need only induce protective titer, although the duration of the response and induction of immunologic memory are critical for maintaining protection. Induction of cell-mediated immunity is a requirement for protection against many etiologic agents, but is also partly responsible for side effects of adjuvants.
Adjuvants or immunopotentiators were initially thought of as agents capable of promoting an augmented and more sustained antibody response. However, new evidence has shown that adjuvants influence titer, duration, isotype, and avidity of antibody, as well as affect properties of cell-mediated immunity (CMI) ( Table 1) (Hunter et al., 1995) . For example, adjuvants have been shown to induce class I-restricted CD8-positive cytotoxic T lymphocytes and modulate the specificity of antibody among available epitopes on protein antigens (Takahashi et al., 1990; Kenney et al., 1989) .
Adjuvants can be categorized according to their origins (whether they are derived from mineral; bacterial; plant; synthetic; or host product, such as Interleukin 1 and 2), and according to their proposed mechanism of action. Certain adjuvants such as alum, oil emulsions, liposomes, and synthetic polymers act through the effect of antigen localization ("depot" effect), which leads to slow delivery of the antigen. Most adjuvants also induce complex cell interactions between macrophages and lymphocytes.
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Investigators and research staff should not overlook the pain and distress that adjuvant-related protocols can cause in laboratory animals. Most of these protocols are accompanied by undesirable side effects that range in severity and duration and are usually caused by the adjuvant. To date, there is no agreement as to the level of discomfort adjuvants induce in laboratory animals with respect to the U.S. Department of Agriculture classification scheme on pain and distress. Aside from general signs of discomfort such as anorexia, weight loss, and lethargy, underlying conditions such as irritation at the site of injection and abdominal distention due to ascites production in mice require veterinary care and monitoring. If neither of these measures can be provided, affected animals should be euthanized immediately according to an approved method.
FREUND'S COMPLETE AND INCOMPLETE ADJUVANTS
In 1937, Jules Freund reported the discovery of elevated titers in tuberculous guinea pigs injected with sheep erythrocytes (Freund et al., 1937) . This finding led him to examine the effect of emulsifying an aqueous solution of the antigen ovalbumin in paraffin oil containing killed tubercle bacilli with the aid of a surfactant. After further development, this resulted in Freund's complete adjuvant (FCA), a water-in-oil emulsion of mineral oil, mannide monooleate (a surfactant), (Freund, 1951) . Some commercial preparations contain M. butyricum instead of M. tuberculosis (Stewart-Tull, 1995) . FCA is a potent adjuvant that stimulates both humoral and cell-mediated immunity, and preferentially induces antibody against epitopes on denatured proteins. However, its toxicity has limited its use to laboratory animals only. The toxicity occurs because the mineral oil cannot be metabolized and the mycobacterial elements can elicit severe granulomatous reactions. Freund's incomplete adjuvant (FIA) is the same as FCA, except that killed mycobacterial cells or cellular components are absent. Both FCA and FIA contain the antigen in the aqueous phase of the emulsion. FIA is less effective for inducing high antibody titers and enhancing cell-mediated immunity than FCA, but it is still an effective adjuvant and is much less toxic than FCA. In fact, its use in human vaccines is being revived.
Water-in-oil emulsions sequester the antigen and release it over long periods, up to 6 months or more after injection, which induces high titers as long as the antigen is stable. This is an important factor to consider when planning booster schedules. Also, because these emulsions contain antigen in the aqueous phase, it is important to know the chemical nature of the antigen being used. The depot effect is the hallmark of these types of emulsions, but other complex effects on cells of the immune system, such as nonspecific stimulation and alteration on cellular interactions, also occur. Furthermore, FCA not only localizes the antigen to its initial depot, but also disseminates it to lymph nodes, which may be more important for its adjuvant activity (Waksman, 1979) . FCA is normally administered with equal volumes of antigen, that is, one part FCA or less with one part antigen. The concentration of mycobacteria varies greatly among commercial brands; if kept at 0.5 mg/ml or lower, less severe inflammatory reactions result. A general rule is that FCA should be used only for weakly immunogenic antigens and only for initial immunizations. FIA should be used for subsequent immunizations. Numerous reports of animal studies in which FCA was administered using multiple subcutaneous injections have shown not only that severe systemic reactions and local ulcerations are likely, but also that immune response to protein antigens can be decreased rather than increased (Stewart-Tull, 1995) .
The biological activities of FCA and FIA have to do in part with the stable emulsions they form when properly prepared. This provides the slow release of antigen and protects it from rapid degradation. In addition, FCA and FIA may contain substances that directly stimulate the immune system (Osebold, 1982) . The inclusion of heat-killed mycobacteria in FCA induces the aggregation of macrophages at the site of injection and culminates in a delayed-type hypersensitivity (DTH) granulomatous reaction which, on occasion, may metastasize. Therefore, the combination of the nonmetabolizable mineral oil and the mycobacterial elements make FCA too toxic for use other than in a preclinical setting, although there has been increasing pressure to discontinue its use altogether.
RIBI ADJUVANT SYSTEM®
It has been recognized since the nineteenth century that certain microbes and microbial products, especially mycobacteria and lipopolysaccharides (LPS), can be nonspecifically immunostimulatory (Mastrangelo and Berd, 1982; Nauts et al., 1946) . Advances in cellular immunology, microbiology, and vaccine development have since led to a better understanding of how these substances act as adjuvants and to the development of Ribi Adjuvant System® (RAS®). Unlike Freund's adjuvants, Ribi adjuvants are oil-in-water emulsions in which the antigen is blended with a minimal volume of oil and these droplets are then emulsified in a saline solution containing the surfactant Tween 80 (Figure 1) (Ribi et al., 1975) . Although oil-in-water emulsions are less viscous than water-in-oil emulsions and, therefore, easier to inject, they are rather poor adjuvants when given alone. For this reason, immunostimulators are added to enhance the im-munogenicity of the emulsion (Altman and Dixon, 1989) . Some of these agents include two refined products from mycobacteria, trehalose 6,6'-dimycolate (TDM) and cell wall skeleton (CWS), and a purified gram-negative bacterial product, monophosphoryl lipid A (MPL®).
Among the first microbial products investigated for immunostimulant activity were components of the tubercle bacillus and other related mycobacteria (Bekierkunst et al., 1969) . A series of biochemical studies ultimately led to the identification and isolation of TDM, also known as cord factor, which has adjuvant properties (Noll et al., 1956 ). Ribi adjuvants contain this high-molecular weight glycolipid, which is extracted from saprophytic, noncording M. phlei cells (Rudbach et al., 1995) . CWS is a mycobacterial cell wall extract in which the loosely bound lipids, proteins, and carbohydrates have been removed. The remaining compound is a potent immunostimulator that works independently of free TDM (Azuma et al., 1974) . The immunostimulatory activities of CWS can be attributed in part to the polymerized form of muramyl dipeptide (MDP) that it contains (Vosika, 1983) . MDP is largely responsible for the adjuvant activity of whole mycobacterial cells. It has a wide variety of effects on immune responses, including enhancement or suppression of antibody production, depending on time of antigen administration; enhanced cell-mediated immunity; increased nonspecific immunity to bacteria, viruses, fungi, and parasites; stimulation of natural resistance to tumors; induction of autoimmunity; and increased cytokine release (Johnson., 1994) .
LPS is a component of endotoxin of gram-negative bacteria, such as Escherichia coli, which among other effects induces shock. Use of LPS as an adjuvant stems from observations that Haemophilis pertussis enhances immune responses to diphtheria vaccines and tetanus toxoid Webster etal., 1955) . LPS, a complex amphipathic molecule, is a component of the outer membrane of gramnegative organisms and is a particularly potent adjuvant for protein antigens (Johnson et al., 1956) . Both humoral and cell-mediated immunity can be enhanced by LPS, but the severe toxicities of endotoxins render them unacceptable for human use. One component of LPS, a covalently bound lipid, "lipid A," is responsible for most of the biological activities of LPS (Takada and Kotani, 1989) . Lipid A, and certain synthetic derivatives with diminished toxicity resulting from the substitution of fatty acids and removal of phosphate groups, increase humoral and cell-mediated immune responses (Chiller et al., 1973; Kotani et al., 1986) . MPL® (monophosphoryl lipid A) is a key component of most Ribi adjuvants (Table 2) .
Three formulations of RAS® are commercially available for either polyclonal or monoclonal antibody production: (1) TDM emulsion recommended for use with strong immunogens in mice, guinea pigs, and rats; (2) MPL® + TDM emulsion recommended for use in mice, guinea pigs, and rats; and (3) MPL® + TDM + CWS emulsion recommended for use in rabbits, goats, and large animals. The components of each are contained in a metabolizable oil, squalene.
The biological activities of Ribi adjuvants can be attributed to several factors, some of which are specific and others non-specific. MPL® and LPS-like materials are amphipathic and interact with membranes of cells of the immune system (Morrison and Rudbach, 1981) . LPS and TDM bind proteins weakly; however, LPS interacts with specific receptors, and activates multiple cytokines and other mediators of toxic reactions (Morrison, 1990) . LPS is also a B-cell mitogen, which induces production of tumor necrosis factor (TNF). The interaction of LPS and MPL® with cells results in production of interleukin 1 (IL-1), IL-2, IL-6, IL-8, TNF, granulocyte-macrophage colony-stimulating factor (GMCSF), and gamma-interferon (gamma-IFN) (Henricson et al., 1990) . These cytokines enhance antigen uptake, processing, and presentation, which facilitates cellular interactions and immunostimulation (Unanue and Allen, 1987) . Furthermore, MPL® negatively regulates antigen-activated suppressor T cells (Baker, 1988) . Trehalose diester, such as TDM, when emulsified with oil, binds antigen to oil droplets, enhancing their uptake by macrophages (Adam et al., 1973) . Finally, CWS affects macrophages in two ways: lysozyme-mediated digestion of CWS peptidoglycan results in release of soluble MDP particles, which are immunostimulants, and CWS contains high concentrations of mycolic acids, which are also immunostimulatory (Ribi et al., 1978) . RAS® is usually less po- L tent than FCA, but is less toxic and has satisfactory adjuvant activity for many purposes.
TITERMAX®
Studies on the role of lipids in the induction of delayed-type hypersensitivity (DTH) reactions led to the discovery of nonionic block copolymers in the early 1980s (Hunter et al., 1981) . This work deviated from the traditional and dominant paradigm of modern biology, which views biological functions as being controlled to a large extent by specific receptor-ligand interactions. The novel conclusion in this case was that surface free energy, a non-specific property, can influence biological reactions in diverse ways. These copolymers are a special type of surfactant composed of linear blocks or chains of hydrophobic polyoxypropylene (POP) and hydrophilic polyoxyethylene (POE) in different proportions (Hunter and Bennett, 1986) . A broad range of surfaceactive properties can be obtained by varying the size of POP blocks and the ratio of the two components. Because the structure of nonionic block copolymers is flexible, is weak in hydrophobic activity, has limited capacity for intermolecular interactions, and lacks charged groups, these copolymers are less toxic than other surface-active agents (Hunter et al., 1995) . High molecular weight copolymers with hydrophilic moieties flanking hydrophobic moieties form a particular type of adhesive surface and tend to have potent adjuvant properties by favoring chemotaxis, complement activation, and antibody production (Hunter and Bennett, 1986; 1984) . The copolymer CRL-8941 is the immunomodulator component of TiterMax® (Table 2) .
TiterMax® adjuvant forms a microparticulate water-inoil emulsion with CRL-8941 and squalene, a metabolizable oil (Figure 1 ). CRL-8941 is coated with silica particles, which stabilizes the emulsion. This stability is a key property of TiterMax® in that it enables the emulsion to contain a wide variety of antigens without the use of large amounts of toxic emulsifying agents. No sugars, fatty acids, or any other biologically derived materials are incorporated. Some of the antigens that have been tested with TiterMax® include proteins, peptides, polysaccharides conjugates, whole killed viruses, and recombinant proteins (Kalish et al., 1991; van-deWijgert et al., 1991; Byars and Allison, 1987) .
The most basic biological activity of TiterMax®, of which there are several, is that copolymers are able to concentrate more antigen on their surface than can be achieved by comparable concentrations of free antigen in solution. This occurs because the particular surface active characteristics of copolymers allow them to form special adhesive surfaces that are necessary for adjuvant activity. Copolymers with adjuvant properties are insoluble and able to form hydrophilic surfaces by the action of the hydrophilic moieties displacing nearly all of the hydrophobic moieties from the aqueous surface. These surfaces have been shown to activate complement, which influences the localization and retention of antigen in lymphoid tissue and the activation of immunoreactive cells (Hunter and Bennett, 1984) . These copolymers also induce increased expression of class II (la) major histocompatibility molecules (MHC) on macrophages, resulting in an increased ability to present antigen to T cells (Howerton et al., 1990) . Therefore, the antigen bound by adjuvant copolymers on the surface of oil droplets is presented to cells of the immune system in a highly concentrated form. Overall, TiterMax® usually induces antibody titers as high or higher than FCA and with less toxicity.
OTHER ADJUVANTS
Aluminum-based compounds and liposomes are two nonbacterial types of adjuvants that have been used primarily for vaccine development. Alum is the only adjuvant approved for use in human vaccines and is also used in some veterinary vaccines. It is occasionally used in laboratory animal protocols as an adjuvant for antibody production. These compounds appear to induce their effect by the slow release of antigen, as well as by other immunostimulatory properties such as attraction of immunocompetent cells to the injection site (Warren et al., 1986 ). Alum has not been widely used for production of antiserum because it is a relatively weak adjuvant for many antigens and it is deceptively difficult to prepare. Antigens, normally proteins, are physically precipitated with hydrated insoluble salts of aluminum hydroxide or aluminum phosphate. This process can be critically influenced by diverse factors including the concentration of materials, presence of salts, and temperature.
Liposome-type adjuvants are spheres consisting of phospholipid bilayers separated by an aqueous compartment. The charge, composition, method of preparation, and number of layers appear to influence the adjuvant activity, depending on the antigen. Incorporation of protein antigens within such spheres not only protects the antigen from rapid degradation, but also creates a depot effect (Altman and Dixon, 1989) . Furthermore, liposomes mobilize the antigen from the area of injection to the draining lymph nodes, where they interact with antigen-presenting macrophages (Allison and Gregoriadis, 1976) . Incorporating antigens within liposomes can enhance both humoral and cell-mediated immunity, and adding other immunostimulatory agents, such as LPS and MDP, can further increase their immunogenicity (Sanchex et al., 1980; Desiderio and Campbell, 1985) . As with alum compounds, liposomes are undesirable candidates for antibody production because they are difficult to prepare and are not very effective with most antigens.
Adjuvants that are surface-active agents rely on surface free energy of cells to bind to hydrophobic surfaces and bring about their immunostimulatory properties (Allison, 1979) . Lipoteichoic acid of gram-positive organisms, lipid A, and TDM are some of the most potent natural surface-active adjuvants known. Reduction in their adjuvant activity has been associated with alterations in structure that leads to disturbances in surface-active properties. On the other hand, Quil A and QS-21 (saponin-type adjuvants), monophosphoryl lipid A, and lipophilic MDP derivatives have hydrophilic and hydrophobic domains from which their surface-active properties arise (Hunter et al., 1995) . Compounds normally found in the body such as vitamin A and E, and lysolecithin are also considered to be surface-active agents. Other classes of proposed adjuvants include glycan analog, coenzyme Q, amphotericin B, dimethyldioctadecylammonium bromide (DDA), levamisole, and benzimidazole compounds (Bomford, 1980) . None of these are commonly used for production of antisera due to either lack of efficacy or lack of experience.
PAIN AND DISTRESS
FCA has been used in a wide variety of laboratory animals for over 50 years, and there is no question that it can induce chronic pain in both small and large animals (Amyx, 1987) . Researchers have been reluctant to discontinue use of FCA because it is used as a gold standard due to its well known effectiveness with a wide variety of antigens. Therefore, it is important to be familiar with its side effects. Severe clinical pain has been reported in cases of accidental FCA injections (Chapel and August, 1976) , and in cancer patients injected with autologous tumor extract in FCA (Hughes et al., 1970) . In persons previously infected with tuberculosis, accidental injections of even very small amounts of FCA can produce painful lesions that persist for months. The painful reactions were attributed to tuberculin sensitivity. Therefore, in accordance with the U. S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research and Training, "Unless the contrary is established, investigators should consider that procedures that cause pain or distress in human beings may cause pain or distress in other animals" (PHS, 1986, p. 27) . Because of the toxicity associated with the use of FCA, institutional animal care and use committees (IACUCs) should consider the following when reviewing protocols using FCA: (1) whether the investigator has demonstrated why less toxic adjuvants are not suitable for the project, and (2) whether there is special justification for FCA concentration greater than 0.5 mg/ml. Other official guidelines for use of FCA can be obtained from the National Institutes of Health (Grumpstrup-Scott and Greenhouse, 1988 ) and the Canadian Council on Animal Care (CCAC, 1990) .
GRANULOMA FORMATION AT INJECTION SITES
In 1954, Suter and White recognized that peptidoglycolipid from M. tuberculosis in a water-in-oil emulsion injected into the footpad of guinea pigs caused accumulation of epithelioid macrophages (Suter and White, 1954) . Since then, similar inflammatory reactions have been described for intradermal, subcutaneous and intramuscular injections; granulomatous inflammation is consistently present at the sites of inoculation of either FCA or IFA (Broderson, 1989) . In rabbits, intradermal FCA injections commonly cause ulcerations of the skin, and subcutaneous injections produce granulomas at both the injection site and adjacent or distant sites to which the inoculum has migrated. Draining abscesses can also occur at such sites. Intramuscular FCA injections can cause granuloma formation and necrosis of adjacent areas, and "metastatic" granulomas may be found in lymph nodes, lung, kidney, and spleen, depending on the distribution of the emulsion via the lymphatics and circulatory system (Broderson, 1989) . These side effects may culminate in wasting and even death.
ADJUVANT ARTHRITIS
FCA-induced arthritis has been reported in small and large animals. The severity of the lesion varies, and can be very debilitating, especially in larger animals. Lewis rats injected with heat-killed mycobacterial cells suspended in mineral oil develop polyarthritis resulting in the term "adjuvant arthritis" (Pearson, 1956; Pearson and Wood, 1959; Waksman et al., 1960) . F344 and Buffalo rats are less susceptible. One case report describes posterior paresis in guinea pigs caused by inadvertent injections of FCA-antigen mixture into the paraspinal musculature, causing granulomatous infiltration into the spinal canal, which impinged on the spinal cord (Kleinman et al., 1993) . TiterMax®-induced inflammatory reactions have been occasionally observed beginning at 2 or 3 weeks postinjection, intensifying for about another week, and then subsiding. High doses of adjuvant-antigen mixtures per site and toxic antigens may be associated with increased severity of the lesion. By itself, the toxicity of TiterMax® is comparable to that of FIA, which is markedly reduced from that of FCA. Arthus reactions have also been observed at sites of injection with RAS®, although, being an oil-in-water emulsion, such reactions tend to be less severe due to brief retention in the area.
CONCLUSION
No one adjuvant works best with all antigens, animal species, or experimental conditions. Each adjuvant has advantages and disadvantages, and the antigen's properties must also be taken into account to select the adjuvant most likely to give the best results. Although FCA has been considered necessary because of the lack of effective alternatives, this is no longer true. Alternative adjuvants are now available that produce high antibody titers, in some cases exceeding those obtained with FCA and with less severe side effects.
